LitCovid-sample-Enju  

PMC:7253482 / 14484-15383 JSONTXT 23 Projects

Annnotations TAB TSV DIC JSON TextAE Lectin_function IAV-Glycan

Id Subject Object Predicate Lexical cue
T65633 0-2 PRP denotes We
T71210 3-15 VBD denotes hypothesized
T65773 16-20 IN denotes that
T55109 21-39 JJ denotes solvent-accessible
T1585 39-40 -COMMA- denotes ,
T39672 41-51 JJ denotes amino-acid
T20594 52-60 NNS denotes residues
T55010 61-63 IN denotes on
T92344 64-65 NN denotes S
T27449 66-74 NNS denotes proteins
T7753 75-80 MD denotes would
T87805 81-83 VB denotes be
T76109 84-94 VBG denotes undergoing
T49022 95-101 JJR denotes higher
T38215 102-107 NNS denotes rates
T48007 108-110 IN denotes of
T86087 111-120 NNS denotes mutations
T52952 121-129 VBN denotes compared
T99241 130-134 IN denotes with
T30950 135-141 JJ denotes buried
T25052 142-150 NNS denotes residues
T46492 151-154 CC denotes and
T57528 155-162 NNS denotes regions
T50177 163-167 WDT denotes that
T46892 168-171 VBP denotes are
T25102 172-180 VBN denotes occluded
T44481 181-183 IN denotes by
T18790 184-191 NNS denotes glycans
T48178 191-192 -COMMA- denotes ,
T59110 193-198 WDT denotes which
T61432 199-202 VBP denotes are
T59632 203-209 JJ denotes unable
T87545 210-212 TO denotes to
T66630 213-215 VB denotes be
T30435 216-224 VBN denotes targeted
T87263 225-227 IN denotes by
T84547 228-232 NN denotes host
T42560 233-239 JJ denotes immune
T4934 240-249 NNS denotes responses
T73202 251-253 TO denotes To
T86654 254-258 DT denotes that
T62840 259-262 NN denotes end
T60967 262-263 -COMMA- denotes ,
T58857 264-266 PRP denotes we
T3483 267-276 VBD denotes performed
T44308 277-279 DT denotes an
T42487 280-290 NN denotes evaluation
T38057 291-293 IN denotes of
T40313 294-304 JJ denotes amino-acid
T79756 305-320 NN denotes diversification
T74853 321-323 IN denotes on
T83914 324-325 DT denotes a
T53700 326-342 JJ denotes residue-specific
T63979 343-348 NN denotes level
T62380 348-349 -COMMA- denotes ,
T6148 350-355 VBG denotes using
T77953 356-364 RB denotes publicly
T27779 365-374 JJ denotes available
T83161 375-379 NN denotes gene
T25304 380-389 NNS denotes sequences
T83245 390-392 IN denotes of
T52371 393-397 NNP denotes SARS
T61083 398-401 CC denotes and
T72419 402-406 NNP denotes MERS
T42372 407-408 NNP denotes S
T3167 408-409 -COMMA- denotes ,
T70472 410-415 WDT denotes which
T16556 416-419 VBD denotes was
T69286 420-430 VBN denotes calculated
T52989 431-433 IN denotes as
T29326 434-437 DT denotes the
T41479 438-444 NN denotes number
T1834 445-447 IN denotes of
T51205 448-456 VBN denotes observed
T91746 457-465 JJ denotes pairwise
T46357 466-477 NNS denotes differences
T17558 478-485 VBN denotes divided
T41351 486-488 IN denotes by
T50799 489-492 DT denotes the
T28579 493-498 JJ denotes total
T58945 499-505 NN denotes number
T84292 506-508 IN denotes of
T34101 509-517 JJ denotes pairwise
T94055 518-529 NNS denotes comparisons
T18701 531-538 RB denotes Firstly
T74266 538-539 -COMMA- denotes ,
T36827 540-542 PRP denotes we
T39186 543-548 VBD denotes found
T6773 549-553 IN denotes that
T13224 554-564 JJ denotes amino-acid
T54008 565-574 NN denotes diversity
T35302 575-578 VBD denotes was
T93591 579-587 VBN denotes elevated
T90961 588-590 IN denotes at
T69090 591-596 VBN denotes known
T86793 597-605 NNS denotes epitopes
T61088 606-614 VBN denotes targeted
T53019 615-617 IN denotes by
T30461 618-630 VBG denotes neutralizing
T32200 631-641 NNS denotes antibodies
T83554 641-642 -COMMA- denotes ,
T32640 643-647 JJ denotes such
T51281 648-650 IN denotes as
T69890 651-654 DT denotes the
T83248 655-665 JJ denotes N-terminal
T49099 666-672 NN denotes domain
T58919 673-676 CC denotes and
T18721 677-680 DT denotes the
T18570 681-697 JJ denotes receptor-binding
T60790 698-705 NNS denotes domains
T18812 705-706 -COMMA- denotes ,
T96660 707-710 CC denotes and
T11216 711-718 VBN denotes reduced
T27277 719-721 IN denotes in
T89562 722-725 DT denotes the
T7777 726-733 NNS denotes regions
T23472 734-736 IN denotes in
T66095 737-740 DT denotes the
T52990 741-743 NN denotes S2
T69246 744-750 NN denotes domain
T76095 750-751 -COMMA- denotes ,
T33023 752-756 JJ denotes such
T94778 757-759 IN denotes as
T12698 760-763 DT denotes the
T82633 764-770 NN denotes fusion
T75213 771-778 NN denotes peptide
T29294 778-779 -COMMA- denotes ,
T28968 780-786 NN denotes heptad
T29760 787-793 NN denotes repeat
T53742 794-797 CD denotes one
T18725 797-798 -COMMA- denotes ,
T43420 799-802 CC denotes and
T34460 803-806 DT denotes the
T26621 807-814 JJ denotes central
T91466 815-820 NN denotes helix
T93319 821-828 NNS denotes domains
T88231 828-829 -COMMA- denotes ,
T49934 830-835 WDT denotes which
T23715 836-839 VBP denotes are
T33407 840-846 RB denotes likely
T88882 847-854 JJ denotes subject
T76117 855-857 TO denotes to
T4874 858-865 JJR denotes greater
T38302 866-876 JJ denotes functional
T99472 877-888 NNS denotes constraints
T34520 889-890 -LRB- denotes (
T48991 890-897 NN denotes Fig. 4a
T5319 897-898 -RRB- denotes )
R10199 T42372 T61083 arg2Of S,and
R10411 T32200 T83554 arg1Of antibodies,","
R10516 T86793 T76095 arg1Of epitopes,","
R12367 T54008 T35302 arg1Of diversity,was
R1336 T27779 T77953 arg1Of available,publicly
R15085 T88882 T76117 arg1Of subject,to
R15715 T25304 T83161 arg1Of sequences,gene
R16092 T20594 T76109 arg1Of residues,undergoing
R16170 T96660 T18812 arg1Of and,","
R16608 T94778 T33023 arg1Of as,such
R16738 T43420 T94778 arg2Of and,as
R17754 T32200 T61088 arg1Of antibodies,targeted
R17994 T76109 T87805 arg2Of undergoing,be
R18674 T93319 T88231 arg1Of domains,","
R20067 T75213 T82633 arg1Of peptide,fusion
R21254 T46357 T1834 arg2Of differences,of
R21530 T49099 T69890 arg1Of domain,the
R21612 T69286 T52989 arg1Of calculated,as
R22162 T76109 T65773 arg1Of undergoing,that
R22989 T41479 T52989 arg2Of number,as
R23177 T30435 T87545 arg1Of targeted,to
R23301 T52371 T61083 arg1Of SARS,and
R23741 T62840 T86654 arg1Of end,that
R23746 T93319 T91466 arg1Of domains,helix
R24020 T41479 T29326 arg1Of number,the
R25200 T38215 T76109 arg2Of rates,undergoing
R26107 T18790 T25102 arg1Of glycans,occluded
R2636 T25304 T83245 arg1Of sequences,of
R27719 T29760 T28968 arg1Of repeat,heptad
R28264 T46492 T66630 arg1Of and,be
R28386 T46492 T99241 arg2Of and,with
R28443 T3483 T73202 arg1Of performed,To
R28527 T93319 T49934 arg1Of domains,which
R29286 T46492 T48178 arg1Of and,","
R30852 T4934 T42560 arg1Of responses,immune
R3107 T99472 T4874 arg1Of constraints,greater
R31642 T99472 T34520 arg1Of constraints,(
R31717 T46492 T59110 arg1Of and,which
R31827 T46492 T61432 arg1Of and,are
R32729 T69246 T66095 arg1Of domain,the
R3287 T69246 T52990 arg1Of domain,S2
R33105 T41479 T1834 arg1Of number,of
R36620 T46357 T91746 arg1Of differences,pairwise
R36891 T20594 T39672 arg1Of residues,amino-acid
R36961 T93591 T35302 arg2Of elevated,was
R37081 T25102 T46892 arg2Of occluded,are
R38048 T43420 T18725 arg1Of and,","
R3981 T3483 T60967 arg1Of performed,","
R3992 T75213 T12698 arg1Of peptide,the
R40189 T20594 T55010 arg1Of residues,on
R40241 T58945 T28579 arg1Of number,total
R41505 T58945 T41351 arg2Of number,by
R42106 T61083 T70472 arg1Of and,which
R42703 T25304 T27779 arg1Of sequences,available
R44274 T58945 T84292 arg1Of number,of
R44596 T61083 T83245 arg2Of and,of
R46016 T57528 T46492 arg2Of regions,and
R47190 T42487 T44308 arg1Of evaluation,an
R47563 T7777 T27277 arg2Of regions,in
R48506 T36827 T39186 arg1Of we,found
R49061 T59632 T61432 arg2Of unable,are
R49150 T29760 T53742 arg1Of repeat,one
R49770 T49099 T58919 arg1Of domain,and
R4990 T61083 T16556 arg1Of and,was
R49965 T7777 T89562 arg1Of regions,the
R51193 T46357 T17558 arg2Of differences,divided
R52418 T3483 T74853 arg1Of performed,on
R54302 T76109 T7753 arg2Of undergoing,would
R54626 T39186 T18701 arg1Of found,Firstly
R55146 T86793 T90961 arg2Of epitopes,at
R5522 T46492 T30950 arg1Of and,buried
R55552 T39186 T74266 arg1Of found,","
R56401 T69246 T23472 arg2Of domain,in
R56816 T63979 T74853 arg2Of level,on
R56819 T54008 T13224 arg1Of diversity,amino-acid
R56933 T46492 T50177 arg1Of and,that
R56973 T25052 T46492 arg1Of residues,and
R57227 T79756 T40313 arg1Of diversification,amino-acid
R58435 T58945 T50799 arg1Of number,the
R5883 T86793 T69090 arg2Of epitopes,known
R60366 T25304 T6148 arg2Of sequences,using
R60609 T38215 T49022 arg1Of rates,higher
R61595 T46492 T59632 arg1Of and,unable
R61681 T65633 T71210 arg1Of We,hypothesized
R62100 T79756 T38057 arg2Of diversification,of
R62161 T75213 T29294 arg1Of peptide,","
R63756 T63979 T53700 arg1Of level,residue-specific
R64448 T49099 T83248 arg1Of domain,N-terminal
R64991 T38215 T48007 arg1Of rates,of
R65049 T4934 T30435 arg1Of responses,targeted
R65597 T93319 T43420 arg2Of domains,and
R65608 T60790 T58919 arg2Of domains,and
R67157 T54008 T93591 arg2Of diversity,elevated
R6736 T58945 T17558 arg1Of number,divided
R67380 T42487 T38057 arg1Of evaluation,of
R68137 T88882 T23715 arg2Of subject,are
R6866 T69286 T16556 arg2Of calculated,was
R69352 T60790 T18570 arg1Of domains,receptor-binding
R6966 T58919 T51281 arg2Of and,as
R71690 T86793 T11216 arg2Of epitopes,reduced
R71969 T42372 T72419 arg1Of S,MERS
R72203 T20594 T7753 arg1Of residues,would
R72593 T58857 T6148 arg1Of we,using
R72861 T55109 T1585 arg1Of solvent-accessible,","
R73473 T30435 T66630 arg2Of targeted,be
R74212 T32200 T30461 arg1Of antibodies,neutralizing
R74990 T61088 T96660 arg1Of targeted,and
R75726 T48991 T34520 arg2Of Fig. 4a,(
R75794 T94055 T84292 arg2Of comparisons,of
R76231 T63979 T83914 arg1Of level,a
R77034 T39672 T1585 arg2Of amino-acid,","
R77296 T58857 T3483 arg1Of we,performed
R79922 T94055 T34101 arg1Of comparisons,pairwise
R80658 T18790 T44481 arg2Of glycans,by
R81049 T32200 T51281 arg1Of antibodies,as
R81060 T46492 T25102 arg2Of and,occluded
R81192 T6148 T3483 arg3Of using,performed
R81741 T86087 T48007 arg2Of mutations,of
R8222 T3483 T62380 arg1Of performed,","
R82494 T88882 T33407 arg1Of subject,likely
R82820 T99241 T52952 arg2Of with,compared
R83184 T29760 T29294 arg2Of repeat,","
R83504 T32200 T53019 arg2Of antibodies,by
R84039 T75213 T43420 arg1Of peptide,and
R84142 T4934 T87263 arg2Of responses,by
R84300 T99472 T76117 arg2Of constraints,to
R84393 T93319 T26621 arg1Of domains,central
R84767 T4934 T84547 arg1Of responses,host
R84782 T93319 T88882 arg1Of domains,subject
R85221 T20594 T55109 arg1Of residues,solvent-accessible
R85227 T93591 T39186 arg2Of elevated,found
R85283 T7777 T23472 arg1Of regions,in
R85323 T5319 T34520 arg3Of ),(
R86135 T46492 T30435 arg2Of and,targeted
R8726 T11216 T96660 arg2Of reduced,and
R89891 T11216 T27277 arg1Of reduced,in
R90259 T42487 T3483 arg2Of evaluation,performed
R91100 T46492 T46892 arg1Of and,are
R93652 T93319 T34460 arg1Of domains,the
R9367 T86793 T61088 arg2Of epitopes,targeted
R93854 T61083 T69286 arg2Of and,calculated
R94248 T93591 T6773 arg1Of elevated,that
R94463 T62840 T73202 arg2Of end,To
R94608 T61083 T3167 arg1Of and,","
R95057 T60790 T18721 arg1Of domains,the
R95251 T93319 T23715 arg1Of domains,are
R95749 T27449 T55010 arg2Of proteins,on
R95788 T76109 T52952 arg1Of undergoing,compared
R95941 T20594 T87805 arg1Of residues,be
R96091 T76109 T71210 arg2Of undergoing,hypothesized
R96110 T99472 T38302 arg1Of constraints,functional
R96156 T27449 T92344 arg1Of proteins,S
R96223 T86793 T94778 arg1Of epitopes,as
R96524 T30435 T59632 arg2Of targeted,unable
R98281 T51281 T32640 arg1Of as,such
R98488 T46357 T51205 arg2Of differences,observed
R98710 T93591 T90961 arg1Of elevated,at